JP2001521361A - 型別不能ハエモフィルス インフルエンザエ(haemophilus influenzae)のlkpピリン構造遺伝子およびオペロン - Google Patents
型別不能ハエモフィルス インフルエンザエ(haemophilus influenzae)のlkpピリン構造遺伝子およびオペロンInfo
- Publication number
- JP2001521361A JP2001521361A JP50514296A JP50514296A JP2001521361A JP 2001521361 A JP2001521361 A JP 2001521361A JP 50514296 A JP50514296 A JP 50514296A JP 50514296 A JP50514296 A JP 50514296A JP 2001521361 A JP2001521361 A JP 2001521361A
- Authority
- JP
- Japan
- Prior art keywords
- influenzae
- lkp
- protein
- pili
- serotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 188
- 241000606768 Haemophilus influenzae Species 0.000 title claims abstract description 93
- 229940047650 haemophilus influenzae Drugs 0.000 title claims abstract description 52
- 108010000916 Fimbriae Proteins Proteins 0.000 title description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 137
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims abstract description 56
- 108020004414 DNA Proteins 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 38
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 29
- 102000053602 DNA Human genes 0.000 claims abstract description 13
- 241000606790 Haemophilus Species 0.000 claims abstract description 13
- 230000003053 immunization Effects 0.000 claims abstract description 7
- 102100030088 ATP-dependent RNA helicase A Human genes 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 51
- 239000000523 sample Substances 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 11
- 238000009396 hybridization Methods 0.000 claims description 11
- 210000004209 hair Anatomy 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 5
- 101710139195 Nuclear RNA export factor 1 Proteins 0.000 claims description 5
- 108020003215 DNA Probes Proteins 0.000 claims description 4
- 239000003298 DNA probe Substances 0.000 claims description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 4
- 102100035402 Nuclear RNA export factor 1 Human genes 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 2
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 102000005431 Molecular Chaperones Human genes 0.000 claims 1
- 101150066370 hipA gene Proteins 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 238000010367 cloning Methods 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 238000002955 isolation Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 46
- 241000588724 Escherichia coli Species 0.000 description 37
- 101100215613 Arabidopsis thaliana ADO1 gene Proteins 0.000 description 34
- 238000000746 purification Methods 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- 206010022000 influenza Diseases 0.000 description 27
- 239000000872 buffer Substances 0.000 description 26
- 239000008188 pellet Substances 0.000 description 25
- 150000007523 nucleic acids Chemical group 0.000 description 23
- 238000005119 centrifugation Methods 0.000 description 22
- 150000001413 amino acids Chemical group 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 239000000499 gel Substances 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 229920004890 Triton X-100 Polymers 0.000 description 8
- 239000013504 Triton X-100 Substances 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000035931 haemagglutination Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 6
- 210000004885 white matter Anatomy 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 241000588832 Bordetella pertussis Species 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- 241000588655 Moraxella catarrhalis Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010033078 Otitis media Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108010059278 Pyrin Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 102000005583 Pyrin Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007330 chocolate agar Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101000688206 Bos taurus Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 239000008001 CAPS buffer Substances 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000002250 Herpochondria elegans Species 0.000 description 1
- 101001071233 Homo sapiens PHD finger protein 1 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102100036879 PHD finger protein 1 Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid ester Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 101150083849 hifC gene Proteins 0.000 description 1
- 101150028972 hifD gene Proteins 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. (i) a)配列番号4; b)配列番号4の相補鎖;および、 c)配列番号4にハイブリダイズするDNA配列; からなる群より選択される型別不能ハエモフィルス インフルエンザエ(Hae mophilus influenzae)血清型1 LKPオペロンを含む単 離されたDNA配列; (ii) a)配列番号4の内のヌクレオチド1882〜2532; b)a)の相補鎖;および、 c)a)にハイブリダイズするDNA配列; からなる群より選択されるハエモフィルス インフルエンザエ(Haemoph ilus influenzae)血清型1 LKP hipP遺伝子を含む単 離されたDNA配列; (iii) a)配列番号4の内のヌクレオチド2854〜3636; b)a)の相補鎖;および、 c)a)にハイブリダイズするDNA配列; からなる群より選択されるハエモフィルス インフルエンザエ(Haemoph ilus influenzae)血清型1 LKP hipC遺伝子を含む単 離されたDNA配列; (iv) a)配列番号4の内のヌクレオチド4016〜6238; b)a)の相補鎖;および c)a)にハイブリダイズするDNA配列; からなる群より選択されるハエモフィルス インフルエンザエ(Haemoph ilus influenzae)血清型1 LKP hipR遺伝子を含む単 離されたDNA配列; (v) a)配列番号4の内のヌクレオチド6259〜6873; b)a)の相補鎖;および、 c)a)にハイブリダイズするDNA配列; からなる群より選択されるハエモフィルス インフルエンザエ(Haemoph ilus influenzae)血清型1 LKP hipM遺伝子を含む単 離されたDNA配列; (vi) a)配列番号4の内のヌクレオチド6955〜8365; b)a)の相補鎖;および、 c)a)にハイブリダイズするDNA配列; からなる群より選択されるハエモフィルス インフルエンザエ(Haemoph ilus influenzae)血清型1 LKP hipA遺伝子を含む単 離されたDNA配列;ならびに (vii) 配列番号4の内のヌクレオチド6955〜8265を含む ハエモフィルス インフルエンザエ(Haemophilus influen zae )血清型1 LKP 先端付着因子を含む単離されたDNA配列; からなる群より選択される単離されたDNA配列。 2. (a)配列番号5を含むアミノ酸配列を有する血清型1 LKP ピリ ン蛋白質; (b)配列番号6を含むアミノ酸配列を有する血清型1 LKP ペリ プラズムシャペロン蛋白質; (c)配列番号7を含むアミノ酸配列を有する血清型1 LKP 膜ア ンカー蛋白質; (d)配列番号8を含むアミノ酸配列を有する血清型1 LKP 先端 会合蛋白質; (e)配列番号9を含むアミノ酸配列を有する血清型1 LKP 先端 付着因子蛋白質;もしくは、 (f)配列番号3を含むアミノ酸配列を有する血清型1 LKP ピリ ン蛋白質;または それらの生物学的活性断片; からなる群より選択される単離されたハエモフィルス インフルエンザエ(Ha emophilus influenzae)蛋白質。 3. LKP先端付着因子蛋白質の生物学的断片およびマルトース結合性蛋白 質もしくはグルタチオン−S−トランスフェラーゼを含む組換えハエモフィルス インフルエンザエ(Haemophilus influenzae)LKP 先端付着因子融合蛋白質。 4. 配列番号11を含むアミノ酸配列もしくはその生物学的活性断片を有す る組換えハエモフィルス インフルエンザエ(Haemophilus inf luenzae )血清型1 LKP 先端付着因子融合蛋白質。 5. 組換えハエモフィルス インフルエンザエ(Haemophi lus influenzae)血清型 LKP 先端付着因子融合蛋白質で哺 乳類を免疫化することを含む、ハエモフィルス インフルエンザエ(Haemo philus influenzae)LKP 先端付着因子に結合する抗体を 作製する方法。 6. ハエモフィルス インフルエンザエ(Haemophilus inf luenzae )LKP ピリ線毛をコードするDNA挿入断片を含む組換え発 現ベクターであって、前記発現ベクターが原核生物もしくは真核生物の細胞内で 生物学的に活性なLKPピリ線毛を発現することが可能である、上記ベクター。 7. ハエモフィルス インフルエンザエ(Haemophilus inf luenzae )LKP ピリ線毛をコードするDNA挿入断片を含む発現ベク ターで形質転換させた原核生物もしくは真核生物の細胞であって、前記発現ベク ターが宿主細胞内で生物学的に活性なLKPピリ線毛を発現することが可能な、 上記細胞。 8. a)血清型10、血清型11、もしくは血清型12のLKPピリ線毛を コードするDNA配列を、宿主細胞内で生物学的に活性なLKPピリ線毛を発現 することが可能な発現ベクター内に挿入し、そのことによりLKPピリ線毛発現 ベクターを作製する段階;および、 b)段階a)において作製された発現ベクターで適切な宿主細胞をトラ ンスフェクトし、そしてそのトランスフェクト宿主細胞をその宿主細胞内でのL KPピリ線毛の発現に適する条件下て維持する段階; を含む、原核生物もしくは真核生物の宿主細胞内で、ハエモフィルスインフルエ ンザエ(Haemophilus influenzae)の血清型10、血清 型11、血清型12のLKPピリ線毛を作製する方 法。 9. おおまかには配列番号4の内の6955〜8265の間のヌクレオチド を含むハエモフィルス インフルエンザエ(Haemophilus infl uenzae )先端付着因子蛋白質をコードするDNA配列にハイブリダイズす ることが可能なDNAプローブ。 10. ハエモフィルス インフルエンザエ(Haemophilus inf luenzae )先端付着因子蛋白質もしくはその活性断片をコードする組換え DNA分子。 11. ある生物学的試料中のハエモフィルス インフルエンザエ(Haemo philus influenzae)の存在についてアッセイする、その試料 をハイブリダイゼーションに適する条件下で先端付着因子蛋白質をコードするD NA配列にハイブリダイズすることが可能な約400ヌクレオチドを含むDNA プローブと接触させる段階、およびハイブリダイズしたDNAの存在を検出する 段階を含む方法。 12. ある哺乳類をハエモフィルス インフルエンザエ(Haemophil us influenzae)に対して予防接種する、その哺乳類にハエモフィ ルス インフルエンザエ(Haemophilus influenzae)L KP先端付着因子蛋白質もしくはその生物学的活性断片の有効量を投与すること を含む方法。 13. ハエモフィルス インフルエンザエ(Haemophilus inf luenzae )により引き起こされる感染から哺乳類を防御する、その哺乳類 に、ハエモフィルス インフルエンザエ(Haemophilus influ enzae )LKP先端付着因子蛋白質もしくはその生物学的活性断片、および 薬剤学的に許容される担体を含む 組成物の有効量を投与することを含む方法。 14. ハエモフィルス インフルエンザエ(Haemophilus inf luenzae )により引き起こされる感染から哺乳類を防御するための、薬剤 学的に許容される担体、およびハエモフィルス インフルエンザエ(Haemo philus influenzae)LKP先端付着因子蛋白質もしくはその 生物学的活性断片を含むワクチン組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/277,231 | 1994-07-19 | ||
US08/277,231 US5643725A (en) | 1994-07-19 | 1994-07-19 | Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable haemophilus influenzae |
US08/477,326 US5968769A (en) | 1994-07-19 | 1995-06-07 | Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable Haemophilus influenzae |
US08/477,326 | 1995-06-07 | ||
US08/473,750 US5834187A (en) | 1994-07-19 | 1995-06-07 | Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable Haemophilus influenzae |
US08/473,750 | 1995-06-07 | ||
PCT/US1995/008789 WO1996002648A1 (en) | 1994-07-19 | 1995-07-13 | Lkp pilin structural genes and operon of nontypable haemophilus influenzae |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007249223A Division JP2008067707A (ja) | 1994-07-19 | 2007-09-26 | 分類不可能なハエモフィルスインフルエンザエのlkpピリン構造遺伝子およびオペロン |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001521361A true JP2001521361A (ja) | 2001-11-06 |
Family
ID=27402882
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50514296A Pending JP2001521361A (ja) | 1994-07-19 | 1995-07-13 | 型別不能ハエモフィルス インフルエンザエ(haemophilus influenzae)のlkpピリン構造遺伝子およびオペロン |
JP2007249223A Pending JP2008067707A (ja) | 1994-07-19 | 2007-09-26 | 分類不可能なハエモフィルスインフルエンザエのlkpピリン構造遺伝子およびオペロン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007249223A Pending JP2008067707A (ja) | 1994-07-19 | 2007-09-26 | 分類不可能なハエモフィルスインフルエンザエのlkpピリン構造遺伝子およびオペロン |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0771352B1 (ja) |
JP (2) | JP2001521361A (ja) |
KR (1) | KR100391483B1 (ja) |
AT (1) | ATE315648T1 (ja) |
AU (1) | AU706937B2 (ja) |
CA (1) | CA2195090C (ja) |
DE (1) | DE69534747T2 (ja) |
DK (1) | DK0771352T3 (ja) |
ES (1) | ES2257741T3 (ja) |
PT (1) | PT771352E (ja) |
WO (1) | WO1996002648A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008504011A (ja) * | 2003-12-23 | 2008-02-14 | チルドレンズ ホスピタル, インコーポレイテッド | HaemophilusinfluenzaeIV型ピリ線毛 |
JP2008067707A (ja) * | 1994-07-19 | 2008-03-27 | Wyeth Holdings Corp | 分類不可能なハエモフィルスインフルエンザエのlkpピリン構造遺伝子およびオペロン |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020055101A1 (en) | 1995-09-11 | 2002-05-09 | Michel G. Bergeron | Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
US6001564A (en) * | 1994-09-12 | 1999-12-14 | Infectio Diagnostic, Inc. | Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
US5646259A (en) | 1995-03-24 | 1997-07-08 | St. Louis University | DNA encoding haemophilus adhesion proteins |
AU754024B2 (en) * | 1995-03-24 | 2002-10-31 | St. Louis University | Haemophilus adhesion proteins |
US5750116A (en) * | 1995-06-02 | 1998-05-12 | Bactex, Inc. | Haemophilus influenzae pilus vaccines |
US5994066A (en) * | 1995-09-11 | 1999-11-30 | Infectio Diagnostic, Inc. | Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
WO2001023604A2 (en) | 1999-09-28 | 2001-04-05 | Infectio Diagnostic (I.D.I.) Inc. | Highly conserved genes and their use to generate probes and primers for detection of microorganisms |
US20030049636A1 (en) | 1999-05-03 | 2003-03-13 | Bergeron Michel G. | Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories |
US20100267012A1 (en) | 1997-11-04 | 2010-10-21 | Bergeron Michel G | Highly conserved genes and their use to generate probes and primers for detection of microorganisms |
US6335182B1 (en) | 1999-03-16 | 2002-01-01 | Aventis Pasteur Limited | Recombinant Haemophilus influenzae adhesin proteins |
US7785609B1 (en) | 1999-03-16 | 2010-08-31 | Sanofi Pasteur Limited | Recombinant Haemophilus influenzae adhesin proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012460A1 (en) * | 1988-06-16 | 1989-12-28 | Bactex, Inc. | Haemophilus influenzae pilus vaccines |
GB9205704D0 (en) * | 1992-03-16 | 1992-04-29 | Connaught Lab | High molecular weight membrane proteins of non-typeable haemophilus |
CA2195090C (en) * | 1994-07-19 | 2011-04-19 | Bruce A. Green | Lkp pilin structural genes and operon of nontypable haemophilus influenzae |
-
1995
- 1995-07-13 CA CA2195090A patent/CA2195090C/en not_active Expired - Fee Related
- 1995-07-13 PT PT95926676T patent/PT771352E/pt unknown
- 1995-07-13 DK DK95926676T patent/DK0771352T3/da active
- 1995-07-13 ES ES95926676T patent/ES2257741T3/es not_active Expired - Lifetime
- 1995-07-13 DE DE69534747T patent/DE69534747T2/de not_active Expired - Lifetime
- 1995-07-13 EP EP95926676A patent/EP0771352B1/en not_active Expired - Lifetime
- 1995-07-13 JP JP50514296A patent/JP2001521361A/ja active Pending
- 1995-07-13 WO PCT/US1995/008789 patent/WO1996002648A1/en active IP Right Grant
- 1995-07-13 KR KR1019970700328A patent/KR100391483B1/ko not_active IP Right Cessation
- 1995-07-13 AT AT95926676T patent/ATE315648T1/de not_active IP Right Cessation
- 1995-07-13 AU AU30972/95A patent/AU706937B2/en not_active Ceased
-
2007
- 2007-09-26 JP JP2007249223A patent/JP2008067707A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008067707A (ja) * | 1994-07-19 | 2008-03-27 | Wyeth Holdings Corp | 分類不可能なハエモフィルスインフルエンザエのlkpピリン構造遺伝子およびオペロン |
JP2008504011A (ja) * | 2003-12-23 | 2008-02-14 | チルドレンズ ホスピタル, インコーポレイテッド | HaemophilusinfluenzaeIV型ピリ線毛 |
Also Published As
Publication number | Publication date |
---|---|
AU706937B2 (en) | 1999-07-01 |
WO1996002648A1 (en) | 1996-02-01 |
KR100391483B1 (ko) | 2003-10-30 |
ES2257741T3 (es) | 2006-08-01 |
EP0771352B1 (en) | 2006-01-11 |
CA2195090C (en) | 2011-04-19 |
DE69534747D1 (de) | 2006-04-06 |
CA2195090A1 (en) | 1996-02-01 |
EP0771352A1 (en) | 1997-05-07 |
DK0771352T3 (da) | 2006-03-06 |
DE69534747T2 (de) | 2006-07-06 |
PT771352E (pt) | 2006-05-31 |
ATE315648T1 (de) | 2006-02-15 |
AU3097295A (en) | 1996-02-16 |
JP2008067707A (ja) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008067707A (ja) | 分類不可能なハエモフィルスインフルエンザエのlkpピリン構造遺伝子およびオペロン | |
RU1787165C (ru) | Способ получени антигенного препарата, обладающего адгезивными свойствами, из фимбрий | |
AU666329B2 (en) | Methods and compositions relating to useful antigens of (moraxella catarrhalis) | |
JPH09500538A (ja) | ナイセリア・メニンギチジス外膜グループbポーリンタンパク質の高レベル発現、精製および再生 | |
CN101684148A (zh) | 脑膜炎奈瑟氏球菌的新表面蛋白 | |
JPH06504446A (ja) | 肺炎球菌タンパクの構造遺伝子 | |
CN107383201A (zh) | 包含流感嗜血杆菌蛋白e和菌毛蛋白a的融合蛋白和组合疫苗 | |
US8114971B2 (en) | Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells | |
Oaks et al. | Molecular cloning and expression of Rickettsia tsutsugamushi genes for two major protein antigens in Escherichia coli | |
US5874300A (en) | Campylobacter jejuni antigens and methods for their production and use | |
WO1996002648A9 (en) | Lkp pilin structural genes and operon of nontypable haemophilus influenzae | |
US6268171B1 (en) | Recombinant PilC proteins, methods for producing them and their use | |
JP2003527100A (ja) | タンパク質 | |
KR19990087436A (ko) | 치주염의 진단 및 치료용 포르피로모나스 긴기발리스 항원 | |
JP2002510970A (ja) | クラミジア・ニューモニエ由来の表面露出タンパク質 | |
KR0170752B1 (ko) | 혈호균속 인플루엔자용 백신과 진단검사법 | |
DE60036555T2 (de) | Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter | |
JPH022357A (ja) | ヘモフィルス・インフルエンゼb型主外層膜蛋白質抗原の製造方法および組成物 | |
US5834187A (en) | Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable Haemophilus influenzae | |
JP2001292786A (ja) | Salmonellatyphiの外膜タンパク質をコードする遺伝子およびそのタンパク質 | |
US5968769A (en) | Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable Haemophilus influenzae | |
US5750116A (en) | Haemophilus influenzae pilus vaccines | |
US6432669B1 (en) | Protective recombinant Haemophilus influenzae high molecular weight proteins | |
JP2001504335A (ja) | ストレプトコッカス・ユベリスのラクトフェリン結合タンパク質 | |
JP2002534960A (ja) | ワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060228 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20060228 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070926 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080917 |